Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism

[1]  Neil A. McDonald,et al.  Generation and functional characterization of fluorescent, N-terminally tagged CB1 receptor chimeras for live-cell imaging , 2007, Molecular and Cellular Neuroscience.

[2]  A. Boddy,et al.  Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo , 2007, British Journal of Cancer.

[3]  B. Giros,et al.  Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain , 2007, Neuroscience.

[4]  Y. Shoyama,et al.  Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. , 2006, European journal of pharmacology.

[5]  R. Drucker-Colín,et al.  Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats , 2006, FEBS letters.

[6]  Y. Shoyama,et al.  Antipsychotics improve Δ9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice , 2006, Pharmacology Biochemistry and Behavior.

[7]  C. Hillard,et al.  Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Lichtman,et al.  Interactions between THC and cannabidiol in mouse models of cannabinoid activity , 2006, Psychopharmacology.

[9]  C. Tränkle,et al.  Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[10]  E. Russo,et al.  Agonistic Properties of Cannabidiol at 5-HT1a Receptors , 2005, Neurochemical Research.

[11]  A. Young,et al.  Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential , 2005, Journal of psychopharmacology.

[12]  D. Osei-Hyiaman,et al.  Evidence for novel cannabinoid receptors. , 2005, Pharmacology & therapeutics.

[13]  B. Ersbøll,et al.  A Library of 7TM Receptor C-terminal Tails , 2004, Journal of Biological Chemistry.

[14]  M. Fujiwara,et al.  New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. , 2004, Journal of pharmacological sciences.

[15]  J. Rossier,et al.  Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor* , 2004, Journal of Biological Chemistry.

[16]  B. Martin,et al.  Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. , 2002, Chemistry and physics of lipids.

[17]  Raphael Mechoulam,et al.  Cannabidiol: An Overview of Some Pharmacological Aspects , 2002, Journal of clinical pharmacology.

[18]  K. Mishima,et al.  Characteristics of learning and memory impairment induced by delta9-tetrahydrocannabinol in rats. , 2001, Japanese journal of pharmacology.

[19]  J. Nie,et al.  Structural Domains of the CB1 Cannabinoid Receptor That Contribute to Constitutive Activity and G-Protein Sequestration , 2001, The Journal of Neuroscience.

[20]  D. Ponde,et al.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide , 2001, British journal of pharmacology.

[21]  S. Goldberg,et al.  Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys , 2000, Nature Neuroscience.

[22]  R. Blakely,et al.  Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. , 2000, The Journal of pharmacology and experimental therapeutics.

[23]  F. Bloom,et al.  Neuroscience of Addiction , 1998, Neuron.

[24]  I. Yamamoto,et al.  Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. , 1996, Biological & pharmaceutical bulletin.

[25]  L. Benet,et al.  Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[26]  A. Grace,et al.  Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[27]  R. Mechoulam,et al.  Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs , 1991, Pharmacology Biochemistry and Behavior.

[28]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Y. Yim,et al.  Low doses of accumbens dopamine modulate amygdala suppression of spontaneous exploratory activity in rats , 1989, Brain Research.

[30]  I. Yamamoto,et al.  Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol. , 1987, Biochemical pharmacology.

[31]  M. Witter,et al.  Organization of the projections from the subiculum to the ventral striatum in the rat. A study using anterograde transport of Phaseolus vulgaris leucoagglutinin , 1987, Neuroscience.

[32]  F. Fonnum,et al.  Biochemical evidence for glutamate as a transmitter in hippocampal efferents to the basal forebrain and hypothalamus in the rat brain , 1980, Neuroscience.

[33]  D. Olton,et al.  Remembrance of places passed: Spatial memory in rats. , 1976 .

[34]  E. Carlini,et al.  Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. , 1974, European journal of pharmacology.

[35]  E. Carlini,et al.  Pharmacological interaction between cannabidiol and δ9-tetrahydrocannabinol , 1973, Psychopharmacologia.

[36]  I. G. Karniol,et al.  Pharmacological interaction between cannabinol and δ9-tetrahydrocannabinol , 1973, Psychopharmacologia.

[37]  R. Pertwee,et al.  A metabolic interaction in vivo between cannabidiol and Δ1‐tetrahydrocannabinol , 1972, British journal of pharmacology.

[38]  K. Abe,et al.  The serotonin1A receptor agonist 8-OHDPAT reverses Δ9-tetrahydrocannabinol-induced impairment of spatial memory and reduction of acetylcholine release in the dorsal hippocampus in rats , 2009, Neurotoxicity Research.

[39]  D. Baker,et al.  In silico patent searching reveals a new cannabinoid receptor. , 2006, Trends in pharmacological sciences.

[40]  G. Guy,et al.  A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. , 2006, Medical hypotheses.

[41]  M. T. Ham,et al.  Absence of interaction between δ9-tetrahydrocannabinol (δ9-THC) and cannabidiol (CBD) in aggression, muscle control and body temperature experiments in mice , 2004, Psychopharmacologia.

[42]  H. Coper,et al.  Modification of Δ9-THC-actions by cannabinol and cannabidiol in the rat , 2004, Psychopharmacologia.

[43]  D. Jackson,et al.  Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions , 2004, Psychopharmacologia.

[44]  A. Zuardi,et al.  Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects , 2004, Psychopharmacology.

[45]  M. Fujiwara.  [Characteristics of abnormal behavior induced by delta 9-tetrahydrocannabinol in rats]. , 2001, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[46]  L. Benet,et al.  Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[47]  S A Deadwyler,et al.  Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. , 1993, The Journal of pharmacology and experimental therapeutics.